![Multi-Center, Open-Label, Prospective, Randomized, Parallel Group, Long-Term Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a CNI [Calcineurin-inhibitors] -Free Regimen and a CNI-Low Dose Regimen](https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/Adis_logo.png "Multi-Center, Open-Label, Prospective, Randomized, Parallel Group, Long-Term Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a CNI [Calcineurin-inhibitors] -Free Regimen and a CNI-Low Dose Regimen"){kind=logo}
Trial Profile
Multi-Center, Open-Label, Prospective, Randomized, Parallel Group, Long-Term Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a CNI [Calcineurin-inhibitors] -Free Regimen and a CNI-Low Dose Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Mycophenolate mofetil; Mycophenolate sodium; Mycophenolic acid; Sirolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms HERAKLES
- Sponsors Novartis; Novartis Pharmaceuticals
- 02 May 2018 Results (n=417) of five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy, were published in the American Journal of Transplantation.
- 23 Aug 2016 5 year follow up results presented at the 26th International Congress of the Transplantation Society.
- 16 Sep 2015 Results of 48 months follow up presented at the 17th Congress of the European Society for Organ Transplantation